The Neurobiological Effect of 5-HT2AR Modulation
ConditionBasic Science
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorGitte Moos Knudsen
About this trial
The investigators wish to investigate neurobiological effects of serotonin 2A receptor modulation in healthy volunteers, contrasting effects of an agonist (psilocybin) and an antagonist (ketanserin). Magnetic resonance imaging (MRI) and positron emission tomography (PET) will be used as neuroimaging tools.
Eligibility criteria
Qualifiers
None
Disqualifiers
Presence of or previous primary psychiatric disease (DSM axis 1 or WHO ICD-10 diagnostic classifications) or in first-degree relatives.
Previous or present neurological condition/disease, significant somatic condition/disease or intake of drugs suspected to influence test results.
Non-fluent Danish language skills.
Vision or hearing impairment.
Trial design
Treatments tested in this trial
- Psilocybine
- Ketanserin
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Gitte Moos Knudsen
Lead sponsor
Rigshospitalet, Denmark
Sponsor institution
Source ClinicalTrials.gov